lobbying_activities: 2680625

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2680625	875b3d2f-5d28-4a21-9296-c2980e5aa947	Q3	FOLEY & LARDNER LLP	15042	ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY	2021	third_quarter	PHA	FDA issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market.	HOUSE OF REPRESENTATIVES,SENATE	70000		0	0	2021-10-14T15:30:18.290000-04:00